September 12, 2024 01:50 PM EDT
FDA+

FDA re­vis­its new struc­ture for drug re­view doc­u­ments, aim­ing to bet­ter ex­plain its de­ci­sions

Zachary Brennan

Senior Editor

Back in 2019, as part of a pro­gram fo­cused on im­prov­ing doc­u­men­ta­tion and com­mu­ni­ca­tions for drug ap­provals, the FDA made a change to how it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

Cigna sues FTC, call­ing for with­draw­al of 'bi­ased, er­ro­neous' PBM re­port

Af­ter land­ing a key win in a com­mon can­cer con­di­tion, Pfiz­er faces a big test in Phase 3

No­var­tis’ Kisqali snags FDA ap­proval to re­duce re­cur­rence in pa­tients with ear­ly forms of breast can­cer

23andMe heads to ES­MO to tout its two clin­i­cal-stage drugs af­ter scrap­ping dis­cov­ery team

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times